Top

Journal of Cardiovascular Translational Research

Published in:

01-04-2015

Short-Term Adjuvant Therapy with Terminalia arjuna Attenuates Ongoing Inflammation and Immune Imbalance in Patients with Stable Coronary Artery Disease: In Vitro and In Vivo Evidence

Authors: Divya Kapoor, Dimple Trikha, Rajesh Vijayvergiya, K. K. Parashar, Deepak Kaul, Veena Dhawan

Published in: Journal of Cardiovascular Translational Research | Issue 3/2015

Abstract

The present study evaluated the cardioprotective effects of Terminalia arjuna on classical and immuno-inflammatory markers in coronary artery disease (CAD) as an adjuvant therapy. One hundred sixteen patients with stable CAD were administered placebo/T. arjuna (500 mg twice a day) along with medications in a randomized, double-blind clinical trial. To understand the specificity and efficacy of T. arjuna, we evaluated its effect through microarray and in silico analysis in few representative samples. Data was further validated via real-time PCR (n = 50) each at baseline, 3 months, and 6 months, respectively. rIL-18 cytokine was used to induce inflammation in vitro to compare its effects with atorvastatin. T. arjuna significantly down-regulated TG, VLDL-C, and immuno-inflammatory markers in stable CAD versus placebo-treated subjects. Microarray and pathway analysis of a few samples from T. arjuna/placebo-treated groups and real-time PCR validation further confirmed our observations. Our data demonstrate the anti-inflammatory and immunomodulatory effects of T. arjuna that may attenuate ongoing inflammation and immune imbalance in medicated CAD subjects.

Available only for authorised users

Hanson, M. A., Fareed, M. T., Argenio, S. L., Agunwamba, A. O., & Hanson, T. R. (2013). Coronary artery disease. Primary Care, 40, 1–16.CrossRefPubMed

Gupta, R., Joshi, P., Mohan, V., Reddy, K. S., & Yusuf, S. (2008). Epidemiology and causation of coronary heart disease and stroke in India. Heart, 94, 16–26.CrossRefPubMed

Mahajan, N., Malik, N., Bahl, A., & Dhawan, V. (2009). Receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in non-diabetic subjects with pre-mature coronary artery disease. Atherosclerosis, 207, 597–602.CrossRefPubMed

Libby, P. (2012). Inflammation in atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 32, 2045–2051.CrossRefPubMedCentralPubMed

Daviglus, M. L., Lloyd-Jones, D. M., & Pirzada, A. (2006). Preventing cardiovascular disease in the 21st century: therapeutic and preventive implications of current evidence. American Journal Cardiovascular Drugs, 2006(6), 87–101.CrossRef

Kapoor, D., Trikha, D., Vijayvergiya, R., Kaul, D., & Dhawan, V. (2014). Conventional therapies fail to target inflammation and immune imbalance in subjects with stable coronary artery disease: a system-based approach. Atherosclerosis, 237, 4623–4631.CrossRef

Szauter, M. K., Jansen, K. M., Okimoto, G., Loomis, M., Kimura, J. H., Heller, M., et al. (2011). Persistent inflammatory pathways associated with early onset myocardial infarction in a medicated multiethnic Hawaiian cohort. Biochemistry Insights, 4, 13–27.CrossRef

Gillespie, S., & Gavins, F. N. (2013). Phytochemicals: countering risk factors and pathological responses associated with ischemia reperfusion injury. Pharmacology and Therapeutics, 138, 38–45.CrossRefPubMed

Mittal, A., Mahajan, N., Vijayvergiya, R., & Dhawan, V. (2010). Modulation of gene expression by Polyalthia longifolia in postmenopausal women with coronary artery disease: an in vitro study. Journal of Cardiovascular Translational Research, 3, 570–579.CrossRefPubMed

10.

Mahajan, N., Dhawan, V., Sharma, G., Jain, S., & Kaul, D. (2008). Induction of inflammatory gene expression by THP-1 macrophages cultured in normocholesterolemic hypertensive sera and modulatory effects of green tea polyphenols. Journal of Human Hypertension, 22, 141–143.CrossRefPubMed

11.

Maulik, S. K., & Talwar, K. K. (2012). Therapeutic potential of Terminalia arjuna in cardiovascular disorders. American Journal of Cardiovascular Drugs, 12, 157–163.CrossRefPubMed

12.

Kapoor, D., Vijayvergiya, R., & Dhawan, V. (2014). Terminalia arjuna in coronary artery disease: ethnopharmacology, pre-clinical, clinical & safety evaluation. Journal of Ethnopharmacology, 155, 1029–1045.CrossRefPubMed

13.

Oberoi, L., Akiyama, T., Lee, K. H., & Liu, S. J. (2011). The aqueous extract, not organic extracts, of Terminalia arjuna bark exerts cardiotonic effect on adult ventricular myocytes. Phytomedicine, 18, 259–265.CrossRefPubMed

14.

Parveen, A., Babbar, R., Agarwal, S., Kotwani, A., & Fahim, M. (2011). Mechanistic clues in the cardioprotective effect of Terminalia arjuna bark extract in isoproterenol-induced chronic heart failure in rats. Cardiovascular Toxicology, 11, 48–57.CrossRefPubMed

15.

Parveen, A., Babbar, R., Agarwal, S., Kotwani, A., & Fahim, M. (2012). Terminalia arjuna enhances baroreflex sensitivity and myocardial function in isoproterenol-induced chronic heart failure rats. Journal of Cardiovascular Pharmacology and Therapeutics, 17, 199–207.CrossRefPubMed

16.

Subramaniam, S., Ramachandran, S., Uthrapathi, S., Gnamanickam, V. R., & Dubey, G. P. (2011). Anti-hyperlipidemic and antioxidant potential of different fractions of Terminalia arjuna Roxb. bark against PX-407 induced hyperlipidemia. Indian Journal of Experimental Biology, 49, 282–288.PubMed

17.

Subramaniam, S., Subramaniam, R., Rajapandian, S., Uthrapathi, S., Gnanamanickam, V. R., & Dubey, G. P. (2011). Anti-atherogenic activity of ethanolic fraction of Terminalia arjuna bark on hypercholesterolemic rabbits. Evidence-based Complementary and Alternative Medicine, 2011, 487916.CrossRefPubMedCentralPubMed

18.

Reddy, T. K., Seshadri, P., Reddy, K. K., Jagetia, G. C., & Reddy, C. D. (2008). Effect of Terminalia arjuna extract on adriamycin-induced DNA damage. Phytotherapy Research, 22, 1188–1194.CrossRefPubMed

19.

Kokkiripati, P. K., Kamsala, R. V., Bashyam, L., Manthapuram, N., Bitla, P., Peddada, V., et al. (2013). Stem-bark of Terminalia arjuna attenuates human monocytic (THP-1) and aortic endothelial cell activation. Journal of Ethnopharmacology, 146, 456–464.CrossRefPubMed

20.

Khaliq, F., Parveen, A., Singh, S., Gondal, R., Hussain, M. E., & Fahim, M. (2013). Improvement in myocardial function by Terminalia arjuna in streptozotocin-induced diabetic rats: possible mechanisms. Journal of Cardiovascular Pharmacology and Therapeutics, 18, 481–489.CrossRefPubMed

21.

Khaliq, F., Parveen, A., Singh, S., Hussain, M. E., & Fahim, M. (2013). Terminalia arjuna improves cardiovascular autonomic neuropathy in streptozotocin-induced diabetic rats. Cardiovascular Toxicology, 13, 68–76.CrossRefPubMed

22.

Malik, N., Dhawan, V., Bahl, A., & Kaul, D. (2009). Inhibitory effects of Terminalia arjuna on platelet activation in vitro in healthy subjects and patients with coronary artery disease. Platelets, 20, 183–190.CrossRefPubMed

23.

Takahashi, H. K., Iwagaki, H., Yoshino, T., Mori, S., Morichika, T., Itoh, H., et al. (2002). Prostaglandin E(2) inhibits IL-18-induced ICAM-1 and B7.2 expression through EP2/EP4 receptors in human peripheral blood mononuclear cells. Journal of Immunology, 168, 4446–4454.CrossRef

24.

Pearson, T. A., Mensah, G. A., Alexander, R. W., Anderson, J. L., Cannon, R. O., Criqui, M., et al. (2003). Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation, 107, 499–511.CrossRefPubMed

25.

Mahajan, N., Bahl, A., & Dhawan, V. (2010). C-reactive protein (CRP) up-regulates the expression of receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in THP-1 cells: inhibitory effects of atorvastatin. International Journal of Cardiology, 142, 273–278.CrossRefPubMed

26.

Mahajan, N., & Dhawan, V. (2010). Inhibition of C-reactive protein induced expression of matrix metalloproteinases by atorvastatin in THP-1 cells. Molecular and Cellular Biochemistry, 338, 77–86.CrossRefPubMed

27.

Mahajan, N., & Dhawan, V. (2010). In-vitro modulation of PPAR-γ and its effector genes by C-reactive protein inTHP-1 cells: effect of atorvastatin. Archives of Medical Research, 41, 154–161.CrossRefPubMed

28.

World Medical Association Declaration of Helsinki. (1998). Recommendations guiding physicians in biomedical research involving human subjects. Cardiovascular Research, 35, 2–3.

29.

Paes, A. H., Bakker, A., & Soe-Agnie, C. J. (1998). Measurement of patient compliance. Pharmacy World and Science, 20, 73–77.CrossRefPubMed

30.

Dwivedi, S., Deepti, G., & Sharma, K. K. (2000). Modification of coronary risk factors by medicinal plants. Journal of Medicinal amd Aromatic Plant Sciences, 22, 616–620.

31.

Bharani, A., Ganguli, A., & Bhargava, K. D. (1995). Salutary effect of Terminalia arjuna in patients with severe refractory heart failure. International Journal of Cardiology, 49, 191–199.CrossRefPubMed

32.

Chander, R., Singh, K., Khanna, A. K., Kaul, S. M., Puri, A., Saxena, R., et al. (2004). Antidyslipidemic and antioxidant activities of different fractions of Terminalia arjuna stem bark. Indian Journal of Clinical Biochemistry, 19, 141–148.CrossRefPubMedCentralPubMed

33.

Gupta, R., Singhal, S., Goyle, A., & Sharma, V. N. (2001). Antioxidant and hypocholesterolaemic effects of Terminalia arjuna tree-bark powder: a randomised placebo-controlled trial. Journal of the Association of Physicians of India, 49, 231–235.PubMed

34.

Khalil, S. (2005). Effect of statin versus Terminalia arjuna on acute myocardial infarction. DNB thesis (Medicine) National Board of Examination, New Delhi, India.

35.

Qin, S., Chena, J., Tanigawaa, S., & Hou, D. X. (2012). Gene expression profiling and pathway network analysis of hepatic metabolic enzymes targeted by baicalein. Journal of Ethnopharmacology, 140, 131–140.CrossRefPubMed

36.

Lampronti, I., Khan, M. T., Borgatti, M., Bianchi, N., & Gambari, R. (2008). Inhibitory effects of Bangladeshi medicinal plant extracts on interactions between transcription factors and target DNA sequences. Evidence-Based Complementary Alternative Medicine, 5, 303–312.CrossRefPubMedCentralPubMed

37.

Karlsen, A., Paur, I., Bøhn, S. K., Sakhi, A. K., Borge, G. I., Serafini, M., et al. (2010). Bilberry juice modulates plasma concentration of NF-KB related inflammatory markers in subjects at increased risk of CVD. European Journal of Nutrition, 49, 345–355.CrossRefPubMed

38.

Castilla, P., Dávalos, A., Teruel, J. L., Cerrato, F., Fernández-Lucas, M., Merino, J. L., et al. (2008). Comparative effects of dietary supplementation with red grape juice and vitamin E on production of superoxide by circulating neutrophil NADPH oxidase in hemodialysis patients. American Journal of Clinical Nutrition, 87, 1053–1061.PubMed

39.

Estruch, R., Sacanella, E., Badia, E., Antúnez, E., Nicolás, J. M., Fernández-Solá, J., et al. (2004). Different effects of red wine and gin consumption on inflammatory biomarkers of atherosclerosis: a prospective randomized crossover trial. Effects of wine on inflammatory markers. Atherosclerosis, 175, 117–123.CrossRefPubMed

40.

Hollman, P. C., Geelen, A., & Kromhout, D. (2010). Dietary flavonol intake may lower stroke risk in men and women. Journal of Nutrition, 140, 600–604.CrossRefPubMed

41.

Broekhuizen, L. N., van Wijk, D. F., Vink, H., Stalmach, A., Crozier, A., Hutten, B. A., et al. (2011). Reduction of monocyte chemoattractant protein 1 and macrophage migration inhibitory factor by a polyphenol-rich extract in subjects with clustered cardiometabolic risk factors. British Journal of Nutrition, 106, 1416–1422.CrossRefPubMed

42.

Jung, M. K., Ha, S., Son, J. A., Song, J. H., Houh, Y., Cho, E., et al. (2012). Polyphenon-60 displays a therapeutic effect on acne by suppression of TLR2 and IL-8 expression via down-regulating the ERK1/2 pathway. Archives for Dermatological Research, 304, 655–663.CrossRef

43.

Ellis, L. Z., Liu, W., Luo, Y., Okamoto, M., Qu, D., Dunn, J. H., et al. (2011). Green tea polyphenol epigallocatechin-3-gallate suppresses melanoma growth by inhibiting inflammasome and IL-1β secretion. Biochemical and Biophysical Research Communications, 414, 551–556.CrossRefPubMedCentralPubMed

44.

Cavalcanti, E., Vadrucci, E., Delvecchio, F. R., Addabbo, F., Bettini, S., Liou, R., et al. (2014). Administration of reconstituted polyphenol oil bodies efficiently suppresses dendritic cell inflammatory pathways and acute intestinal inflammation. PLoS One, 9, e88898.CrossRefPubMedCentralPubMed

45.

Zhang, Y., Zhen, W., Maechler, P., & Liu, D. (2013). Small molecule kaempferol modulates PDX-1 protein expression and subsequently promotes pancreatic β-cell survival and function via CREB. Journal of Nutrition and Biochemistry, 24, 638–646.CrossRef

Title: Short-Term Adjuvant Therapy with Terminalia arjuna Attenuates Ongoing Inflammation and Immune Imbalance in Patients with Stable Coronary Artery Disease: In Vitro and In Vivo Evidence
Authors: Divya Kapoor
Dimple Trikha
Rajesh Vijayvergiya
K. K. Parashar
Deepak Kaul
Veena Dhawan
Publication date: 01-04-2015
Publisher: Springer US
Published in: Journal of Cardiovascular Translational Research / Issue 3/2015
Print ISSN: 1937-5387
Electronic ISSN: 1937-5395
DOI: https://doi.org/10.1007/s12265-015-9620-x

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Short-Term Adjuvant Therapy with Terminalia arjuna Attenuates Ongoing Inflammation and Immune Imbalance in Patients with Stable Coronary Artery Disease: In Vitro and In Vivo Evidence

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2015

Enhancing the Predictive Power of Mutations in the C-Terminus of the KCNQ1-Encoded Kv7.1 Voltage-Gated Potassium Channel

Guidelines for the Isolation and Characterization of Murine Vascular Smooth Muscle Cells. A Report from the International Society of Cardiovascular Translational Research

Absence of Cardiac Benefit with Early Combination ACE Inhibitor and Beta Blocker Treatment in mdx Mice

BNP and Heart Failure: Preclinical and Clinical Trial Data

Concentrations of Highly Sensitive Cardiac Troponin-I Predict Poor Cardiovascular Outcomes and Adverse Remodeling in Chronic Heart Failure

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page